Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
Khan
S
S
Doré
P C
PC
Sewell
W A C
WA
D015415:Biomarkers / Q000097:blood; D002648:Child; D004802:Eosinophilia / Q000139:chemically induced / Q000150:complications / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology*
D015415:Biomarkers; D016756:Immunoglobulins, Intravenous